Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAM-194
- Development stage
- Phase 1
- Lead developer
- Pamplona Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PAM-194 is a topical small molecule inhibitor of Janus kinase 1 (JAK1) currently under development by Pamplona Biotech (Shenzhen) Co., Ltd. for the treatment of atopic dermatitis. By selectively inhibiting JAK1, PAM-194 modulates the signaling pathways of several key pro-inflammatory cytokines, including IL-4, IL-13, and IL-31, which are central to the pathogenesis of skin inflammation and pruritus in atopic dermatitis. The drug is formulated as an ointment to provide localized therapeutic effects while minimizing systemic exposure and the potential for side effects typically associated with oral JAK inhibitors. PAM-194 is currently being evaluated in Phase 1 clinical trials in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.
02
Targets
Beyond the preview
Go deeper on PAM-194.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAM-194.